A recent study suggests that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end traditional diet and exercise plans.
Published data in a leading health publication demonstrates that while obese people often shed about a fifth of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month after stopping.
"Individuals buying these medications should be informed of the danger of quick rebound weight gain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain means a return to original weight in about 18 months.
Weighing Treatments
The study, which examined 37 of studies involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
Researchers point out that people who shed pounds through diet and exercise usually experience a slower weight regain—approximately 100 grams monthly—post-intervention.
Understanding the Fast Regain
Doctors propose the mode of action of the injections accounts for the amplified weight return.
The injections mimic a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Stopping of this medication means hunger is uncontrolled, making excessive eating a significant risk."
An Ongoing Issue?
Health authorities advise the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts contend that, considering the significant potential of weight regain, the therapy should be considered life-long.
This perspective is echoed by pharmaceutical companies, who note that the findings "highlight the persistent nature of obesity," akin to managing conditions like high blood pressure.
User Experiences
Users who have stopped the medication explain a intense return of cravings.
"It was like something that goes on and I was suddenly ravenous," recalled a patient.
The struggle is worsened if patients have not developed permanent lifestyle or habit changes during treatment.
Growing Use
Survey data suggest that millions of people in the UK have tried these injections in the last 12 months, with desire continuing to grow.
- Adoption is more common among women than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Finally, experts caution that while these medications are effective tools for shedding pounds, they are not a standalone fix and long-term success likely depends on combined lifestyle management.
